AMCP is your partner in navigating AI’s transformative potential—ensuring patient-centered, ethically sound, and strategically aligned implementation across pharmacy practice and policy.
JMCP Outserts - Bridging the Gaps in Precision Oncology: Opportunities in Non-Small Cell Lung Cancer
FINDINGS FROM THE AMCP MARKET INSIGHTS PROGRAM | July, 2023
Summary
Lung cancer is the most common cancer worldwide, with non-small cell lung cancer (NSCLC) accounting for approximately 85% of all lung cancers. The National Institutes of Health estimated that cancer care cost the US $208.9 billion in 2020, $23.8 billion of which was due to lung cancer. View the full fundings from the program on JMCP.
For more disease state research, view the Market Insights Program.
Related
Retinal diseases in patients with diabetes pose signi cant challenges for health care systems. With a high treatment burden and advances in durable therapies, managed care organizations can optimize patient care by addressing coverage barriers that impact timely treatment with anti-VEGF therapies. This roadmap outlines essential points to better retinal disease management and improve treatment for populations of patients with diabetes at high risk for blindness.
View our webinar on Managed Care Approaches to Address Unmet Patient Needs in Multiple Sclerosis (MS), a disease affecting nearly 1 million people in the U.S. Despite advancements in treatment, significant gaps remain in access, affordability, and comprehensive care.
Featured News & Resources
See Full CalendarUpcoming Events
AMCP offers a wide variety of educational opportunities, from events and webinars to online training.
